Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses

Area of Science:

• Immunology
• Cancer Biology
• Glycobiology

Background:

• Metastatic potential of tumor cells correlates with selectin ligand expression (sialyl-Lewis x [sLex], sialyl-Lewis a [sLea]).
• Peptide mimetics of sLex/sLea can enhance IgG2a antibodies, promoting Th1 cellular responses.
• L-selectin is expressed on Th1/Th2 T cell populations, suggesting potential for tumor targeting.

Purpose of the Study:

• To investigate the efficacy of multiple antigen peptide (MAP) mimetics of neolactoseries antigens in inducing cellular immune responses.
• To determine if these responses augment anti-tumor activity against L-selectin ligand-expressing tumor cells.

Main Methods:

• Immunization with MAP mimetic of neolactoseries antigens.
• Assessing MHC-dependent peptide-specific cellular response and IFN-gamma production.
• In vitro activation of T lymphocytes with sLex and assessment of L-selectin expression.
• Evaluating cytotoxic T lymphocyte (CTL) activity against sLex-expressing Meth A cells.

Main Results:

• Peptide immunization induced MHC-dependent, peptide-specific cellular response with IFN-gamma production and IgG2a induction.
• T lymphocytes from immunized animals responded to sLex, producing IFN-gamma in an MHC-dependent manner.
• Stimulation by peptide or carbohydrate led to L-selectin loss on CD4+ T cells, confirming Th1 phenotype.
• Enhanced CTL activity against sLex-expressing Meth A cells was observed, inhibited by anti-MHC class I and anti-L-selectin antibodies.

Conclusions:

• Peptide mimetics of tumor-associated carbohydrate antigens can induce Th1 cellular responses and enhance anti-tumor immunity.
• L-selectin plays a role in tumor rejection, potentially through engagement with T cell receptors (TCRs) for processed glycopeptides.
• Focus on peptide mimetics offers a strategy for inducing carbohydrate-reactive cellular responses against tumors.